My watch list  


Systematic (IUPAC) name
CAS number 30652-11-0
ATC code V03AC02
PubChem 2972
Chemical data
Formula C7H9NO2 
Mol. mass 139.152 g/mol
SMILES search in eMolecules, PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism Glucuronidation
Half life 2 to 3 hours
Excretion Renal (75 to 90% in 24 hours)
Therapeutic considerations
Licence data


Pregnancy cat.


Legal status
Routes Oral

Deferiprone (tradenames include Ferriprox) is an oral drug that chelates iron and is used to treat thalassaemia major.[1]

It is currently licenced for use in the Europe and Asia, but not in Canada and the United States.[1]


Deferiprone was at the centre of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and pharmaceutical giant Apotex, that started in 1996.[2] Dr. Olivieri's data suggested that deferiprone lead to progressive hepatic fibrosis, a finding which is in dispute.[3][4]


  1. ^ a b Savulescu J (2004). "Thalassaemia major: the murky story of deferiprone". BMJ 328 (7436): 358-9. PMID 14962851. Full Text.
  2. ^ Viens A, Savulescu J (2004). "Introduction to The Olivieri symposium.". J Med Ethics 30 (1): 1-7. PMID 14872065. Free Full Text.
  3. ^ Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D (2003). "Deferiprone and hepatic fibrosis". Blood 101 (12): 5089-90; author reply 5090-1. PMID 12788794. Full Text.
  4. ^ Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood 100 (5): 1566-9. PMID 12176871. Full Text.

See also

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Deferiprone". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE